Abstract
Blood lipids and metabolites are both markers of current health and indicators of risk for future disease. Here, we describe plasma nuclear magnetic resonance (NMR) biomarker data for 118,461 participants in the UK Biobank, an open resource for public health research with extensive clinical and genomic data. The biomarkers cover 249 measures of lipoprotein lipids, fatty acids, and small molecules such as amino acids, ketones, and glycolysis metabolites. We provide a systematic atlas of associations of these biomarkers to prevalence, incidence, and mortality of over 700 common diseases (biomarker-atlas.nightingale.cloud/). The results reveal a plethora of biomarker associations, including susceptibility to infectious diseases and risk for onset of various cancers, joint disorders, and mental health outcomes, indicating that abundant circulating lipids and metabolites are risk markers well beyond cardiometabolic diseases. Clustering analyses indicate similar biomarker association patterns across different types of diseases, such as liver diseases and polyneuropathies, suggesting latent systemic connectivity in the susceptibility to a diverse set of diseases. The release of NMR biomarker data at scale in the UK Biobank highlights the promise of metabolic profiling in large cohorts for public health research and translation.
Competing Interest Statement
HJ, MT, HK, KN, VM, JN-K, AJK, PS, JB, and PW are employees of Nightingale Health Plc, and hold shares or stock options in Nightingale Health Plc. AC is former employee of Nightingale Health Plc.
Funding Statement
The work was funded by Nightingale Health Plc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for UK Biobank was obtained from the North West Multi-Center Research Ethics Committee. The FINRISK and Health 2000 cohort studies were approved by the Coordinating Ethical Committee of the Helsinki and Uusimaa Hospital District, Finland.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Broken weblink to biomarker-disease atlas fixed. Suboptimal quality for Figure 3 and 5 fixed.
Data Availability
The Nightingale Health NMR biomarker data have been released to the UK Biobank resource in spring 2021 (https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220). The UK Biobank data are available for approved researchers through the UK Biobank data-access protocol. Data from FINRISK and Health 2000 cohorts may be accessed through THL Biobank (https://thl.fi/en/web/thl-biobank). As part of this publication, we provide access to all biomarker-disease summary statistics for academic use through an interactive webtool biomarker-atlas.nightingale.cloud.
https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220
